ESMO 2026

ESMO 2026
October 23-27, 2026
Spain - Madrid

European Society of Medical Oncology.

Explore more information for Gilead Oncology therapies
Material Type
Filter by Keyword(s)

Filter results with keywords such as:

  • Name of author(s)
  • Disease state
  • Indication
  • Trial phase
  • Trial name
  • Trial date

Note: Multiple keywords can be applied at the same time.

    Results (7)

    Exposure-Response Analysis of First-Line Sacituzumab Govitecan Plus Pembrolizumab for Participants With Metastatic Triple-Negative Breast Cancer From the ASCENT-04 Study

    • Author(s): De Azambuja E
    • trodelvy
    • Oncology
    • 1LmTNBC

    Association Between Disease Control and Patient-Reported Functioning and Quality of Life in the ASCENT-03 Study

    • Author(s): Oliveira M
    • trodelvy
    • Oncology
    • 1LmTNBC

    Sacituzumab Govitecan Combined With Enfortumab Vedotin and Zimberelimab in Treatment-Naive Metastatic Urothelial Cancer: Interim Results From Phase 1b TROPHY-U-01 Cohort 7

    • Author(s): Sweis Randy F
    • trodelvy
    • zimberelimab
    • Oncology
    • mUC

    Association Between Disease Control and Patient-Reported Functioning and Quality of Life in the ASCENT-04/KEYNOTE-D19 Study

    • Author(s): Kalinsky K
    • trodelvy
    • Oncology
    • 1LmTNBC

    ASCENT-03: Real-World External Control Arm Analysis of First-Line Sacituzumab Govitecan vs Treatment of Physician’s Choice in Patients With Metastatic Triple-Negative Breast Cancer

    • Author(s): Garrido-Castro A
    • trodelvy
    • Oncology
    • 1LmTNBC

    Subgroup Analysis From the ASCENT-03 Study of Sacituzumab Govitecan vs Chemotherapy in Previously Untreated Metastatic ASCENT-03 Triple-Negative Breast Cancer: PFS by Preselected Chemotherapy, Disease Status, and Brain and Visceral Metastases

    • Author(s): Punie K
    • trodelvy
    • Oncology
    • 1LmTNBC

    Subgroup Analysis From the ASCENT-04/KEYNOTE-D19 Study of Sacituzumab Govitecan + Pembrolizumab vs Chemotherapy + Pembrolizumab in Previously Untreated Metastatic Triple-Negative Breast Cancer: PFS by Preselected Chemotherapy, Disease Status, and Brain

    • Author(s): De Azambuja E
    • trodelvy
    • Oncology
    • 1LmTNBC